170 related articles for article (PubMed ID: 27348415)
1. State of the art in coronary revascularization: Everolimus eluting stents versus multiple arterial grafting.
Benedetto U; Caputo M; Vohra H; Bryan A; Angelini GD
Int J Cardiol; 2016 Sep; 219():345-9. PubMed ID: 27348415
[TBL] [Abstract][Full Text] [Related]
2. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery.
Bangalore S; Guo Y; Samadashvili Z; Blecker S; Xu J; Hannan EL
J Am Coll Cardiol; 2015 Sep; 66(11):1209-1220. PubMed ID: 26361150
[TBL] [Abstract][Full Text] [Related]
3. Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery.
Bangalore S; Guo Y; Samadashvili Z; Blecker S; Hannan EL
Circulation; 2016 May; 133(22):2132-40. PubMed ID: 27151532
[TBL] [Abstract][Full Text] [Related]
4. Everolimus-eluting stents or bypass surgery for multivessel coronary disease.
Bangalore S; Guo Y; Samadashvili Z; Blecker S; Xu J; Hannan EL
N Engl J Med; 2015 Mar; 372(13):1213-22. PubMed ID: 25775087
[TBL] [Abstract][Full Text] [Related]
5. Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease.
Bangalore S; Guo Y; Samadashvili Z; Blecker S; Xu J; Hannan EL
Circ Cardiovasc Interv; 2015 Jul; 8(7):e002626. PubMed ID: 26156152
[TBL] [Abstract][Full Text] [Related]
6. Multiple arterial grafting confers survival advantage compared to percutaneous intervention with drug-eluting stents in multivessel coronary artery disease: A propensity score adjusted analysis.
Raja SG; Benedetto U; Ilsley CD; Amrani M;
Int J Cardiol; 2015; 189():153-8. PubMed ID: 25897895
[TBL] [Abstract][Full Text] [Related]
7. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.
Campos CM; van Klaveren D; Farooq V; Simonton CA; Kappetein AP; Sabik JF; Steyerberg EW; Stone GW; Serruys PW;
Eur Heart J; 2015 May; 36(20):1231-41. PubMed ID: 25583761
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcomes after coronary artery bypass graft versus everolimus-eluting stent implantation in chronic hemodialysis patients.
Kumada Y; Ishii H; Aoyama T; Kamoi D; Sakakibara T; Umemoto N; Ito R; Takahashi H; Murohara T
Coron Artery Dis; 2018 Sep; 29(6):489-494. PubMed ID: 29668554
[TBL] [Abstract][Full Text] [Related]
9. Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.
Lee CW; Ahn JM; Cavalcante R; Sotomi Y; Onuma Y; Suwannasom P; Tenekecioglu E; Yun SC; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Serruys PW; Park SJ
JACC Cardiovasc Interv; 2016 Dec; 9(24):2481-2489. PubMed ID: 28007199
[TBL] [Abstract][Full Text] [Related]
10. Long-term comparative effectiveness of Endeavor zotarolimus-eluting and everolimus-eluting stents in New York.
Qian F; Zhong Y; Hannan EL
Int J Cardiol; 2017 Aug; 241():437-443. PubMed ID: 28389121
[TBL] [Abstract][Full Text] [Related]
11. Improved long-term survival for diabetic patients with surgical versus interventional revascularization.
Kurlansky P; Herbert M; Prince S; Mack MJ
Ann Thorac Surg; 2015 Apr; 99(4):1298-305. PubMed ID: 25686668
[TBL] [Abstract][Full Text] [Related]
12. CABG Versus PCI: Greater Benefit in Long-Term Outcomes With Multiple Arterial Bypass Grafting.
Habib RH; Dimitrova KR; Badour SA; Yammine MB; El-Hage-Sleiman AK; Hoffman DM; Geller CM; Schwann TA; Tranbaugh RF
J Am Coll Cardiol; 2015 Sep; 66(13):1417-27. PubMed ID: 26403338
[TBL] [Abstract][Full Text] [Related]
13. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.
Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
J Am Coll Cardiol; 2018 Jul; 72(4):386-398. PubMed ID: 30025574
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Disease in Diabetics: The BEST Extended Follow-Up Study.
Kim H; Kang DY; Ahn JM; Lee J; Choi Y; Hur SH; Park HJ; Tresukosol D; Kang WC; Kwon HM; Rha SW; Lim DS; Jeong MH; Lee BK; Huang H; Lim YH; Bae JH; Kim BO; Ong TK; Ahn SG; Chung CH; Park DW; Park SJ;
JACC Cardiovasc Interv; 2023 Oct; 16(19):2412-2422. PubMed ID: 37821187
[TBL] [Abstract][Full Text] [Related]
15. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
16. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).
Smits PC; Vlachojannis GJ; McFadden EP; Royaards KJ; Wassing J; Joesoef KS; van Mieghem C; van de Ent M
JACC Cardiovasc Interv; 2015 Aug; 8(9):1157-1165. PubMed ID: 26210806
[TBL] [Abstract][Full Text] [Related]
17. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
[TBL] [Abstract][Full Text] [Related]
18. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
19. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
Zanchin C; Ueki Y; Zanchin T; Häner J; Otsuka T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Moschovitis A; Hunziker L; Valgimigli M; Pilgrim T; Heg D; Windecker S; Räber L
JACC Cardiovasc Interv; 2019 Sep; 12(17):1665-1675. PubMed ID: 31422088
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease.
Chang M; Ahn JM; Lee CW; Cavalcante R; Sotomi Y; Onuma Y; Tenekecioglu E; Han M; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Serruys PW; Park SJ
J Am Coll Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 27364047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
